apollo
0
Written By ,
Reviewed By Dr Aneela Siddabathuni , MPharma., PhD
Last Updated Oct 9, 2024 | 10:52 AM IST

Sigrima 420 mg Injection 14 ml is used in the treatment of Breast cancer. It contains Pertuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in mammalian cells; this causes inhibition of the cancer cell growth and, finally, initiating apoptosis. Sigrima 420 mg Injection 14 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Read more
Prescription drug

Whats That

tooltip
Prescription drug
 Trailing icon
Consult Doctor

Composition

PERTUZUMAB-420MG

Manufacturer/Marketer

Zydus Lifesciences Limited

Consume Type

PARENTERAL

Return Policy

Not Returnable

for this medicine

About Sigrima 420 mg Injection 14 ml

Sigrima 420 mg Injection 14 ml is an anti-cancer medicine used in the treatment of Breast cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. The abnormal growth of cancer (malignant) cells in the breast is known as breast cancer. Sigrima 420 mg Injection 14 ml is combined with trastuzumab and docetaxel for treating patients with HER2-positive metastatic breast cancer who have not received any chemotherapy for metastatic breast cancer. This medicine is also used in combination with docetaxel and trastuzumab as a neoadjuvant treatment of breast cancer in patients with HER2-positive (human epidermal growth factor receptor 2) or as part of a complete treatment regimen for early breast cancer.

Sigrima 420 mg Injection 14 ml contains Pertuzumab as a active ingredient which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

Sigrima 420 mg Injection 14 ml may cause certain side effects such as fatigue, nausea, headache, vomiting, dizziness, hair loss, constipation, dry skin, myalgia, upper respiratory tract infections, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Sigrima 420 mg Injection 14 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Sigrima 420 mg Injection 14 ml should be avoided if you are allergic to it or any other components of this medicine. Sigrima 420 mg Injection 14 ml may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Sigrima 420 mg Injection 14 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Sigrima 420 mg Injection 14 ml along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Sigrima 420 mg Injection 14 ml is not recommended for use in children as the safety and efficacy are not established.

Uses of Sigrima 420 mg Injection 14 ml

Treatment of Breast Cancer

Medicinal Benefits

Sigrima 420 mg Injection 14 ml contains Pertuzumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis. Sigrima 420 mg Injection 14 ml is used in combination with trastuzumab and docetaxel for the treatment of breast cancer.

Directions for Use

A trained oncologist will administer Sigrima 420 mg Injection 14 ml. Hence, do not self-administer.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Sigrima 420 mg Injection 14 ml

  • Nausea
  • Vomiting
  • Dizziness
  • Myalgia
  • Pain at the site of injection
  • Dry skin
  • Hair loss
  • Tiredness
  • Constipation
  • Headache
  • Fatigue
  • Upper respiratory tract infections

Drug Warnings

Sigrima 420 mg Injection 14 ml should be avoided if you are allergic to it or any other components of this medicine. Sigrima 420 mg Injection 14 ml may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Sigrima 420 mg Injection 14 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Sigrima 420 mg Injection 14 ml along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Sigrima 420 mg Injection 14 ml is not recommended for use in children as the safety and efficacy are not established.

Drug Interactions

Drug-Drug Interactions: Sigrima 420 mg Injection 14 ml may interact with anti-cancer drugs (anastrozole, carmustine, daunorubicin), monoclonal antibodies (abciximab, adalimumab), antibiotics (bleomycin),  local anaesthetics (bupivacaine, butacaine).

Drug-Food Interactions: Avoid smoking and alcohol consumption.

Drug-Disease Interactions: Inform your doctor if you have cardiac problems or liver/kidney disease.

Drug-Drug Interactions Checker List

  • ANASTROZOLE
  • CARMUSTINE
  • DAUNORUBICIN
  • ABCIXIMAB
  • BLEOMYCIN
  • BUPIVACAINE

Habit Forming

No

Diet & Lifestyle Advise

  • Meditation and yoga have been proven very effective in helping cancer patients maintain a healthy attitude and body.
  • Eat more lean meats, healthy fats, fruits, vegetables, and whole-grain foods to give you more energy. 
  • Stay hydrated by drinking plenty of water, as dehydration is often seen in cancers.
  • Taking a stroll in the garden or spending 30 minutes of your time doing some light physical activity can be very useful. However, do not over-exert yourself if you feel too tired. 
  • Avoid smoking and alcohol consumption.

Special Advise

  • Avoid intercourse while on treatment with Sigrima 420 mg Injection 14 ml.
  • Regular, complete blood count monitoring is advised.  Also, monitoring of liver function is important while receiving Sigrima 420 mg Injection 14 ml.
  • Sigrima 420 mg Injection 14 ml should not be administered for more than six cycles for patients with early-stage breast cancer.
  • All patients should be tested for HER2 test before starting the treatment regimen.

Disease/Condition Glossary

Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin. 

bannner image

Alcohol

Unsafe

Alcohol intake might increase the risk of worsening your condition. Hence, avoid alcohol consumption till your condition improves.

bannner image

Pregnancy

Unsafe

Sigrima 420 mg Injection 14 ml is not recommended for use in pregnancy as it may harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Sigrima 420 mg Injection 14 ml. Use reliable methods of birth control while on treatment with Sigrima 420 mg Injection 14 ml.

bannner image

Breast Feeding

Caution

It is not known whether Sigrima 420 mg Injection 14 ml is excreted in breast milk. Hence, if you are breastfeeding, inform your doctor before receiving Sigrima 420 mg Injection 14 ml. Your doctor will weigh the benefits and the risks before prescribing this medicine.

bannner image

Driving

Caution

Sigrima 420 mg Injection 14 ml will be administered in the hospital setting. Driving is not recommended while on therapy.

bannner image

Liver

Caution

No clinical trials have assessed the impact of hepatic impairment on the pharmacokinetics of Sigrima 420 mg Injection 14 ml. Hence, if you have a pre-existing or a history of liver disease, inform your doctor.

bannner image

Kidney

Caution

Limited data are available on the effect of Sigrima 420 mg Injection 14 ml in kidney-impaired patients. Hence, if you have a pre-existing or a history of kidney disease, inform your doctor.

bannner image

Children

Unsafe

Sigrima 420 mg Injection 14 ml is not recommended for use in children as the safety and efficacy are not established.

Country of origin

India

Manufacturer/Marketer address

Zydus Corporate Park, 4Th Floor, B Wing, Plot No 103, Near Nirma University,S G Highway, Ahmedabad, 382481
Other Info - SIG0147

FAQs

Sigrima 420 mg Injection 14 ml is used to treat Breast Cancer.
Sigrima 420 mg Injection 14 ml contains Pertuzumab, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.
Inform your doctor whether you have received any other breast cancer treatment containing doxorubicin in your medication list. Sigrima 420 mg Injection 14 ml may cause left ventricular dysfunction, anaphylaxis, hypersensitivity reactions, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, are pregnant, are planning to become pregnant, or are breastfeeding before receiving Sigrima 420 mg Injection 14 ml.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.

Add to Cart